Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
Results of a preliminary study suggest that a treatment called LEA29Y works as well as the standard therapy, cyclosporine, to prevent acute kidney transplant rejection, with less potential for long-term harm to the organ and the patient, and better functioning of the transplanted kidney.
